LXEO logo

LXEO Lexeo Therapeutics, Inc. Common Stock

NASDAQ Global Market · Biotechnology · Healthcare

$2.89
-0.06 (-2.03%)

Lexeo Therapeutics, Inc. is a genetic medicine firm currently in the clinical development phase, dedicated to addressing both inherited and acquired medical conditions. Its robust pipeline features several gene therapy candidates. These include LX2006, an AAVrh10-based therapy aimed at treating cardiomyopathy linked to Friedreich's ataxia (FA); LX2020, another AAVrh10-based candidate targeting arr…

Market Cap: $239.26Mwww.lexeotx.com

Price

No data yet.

Social Signal Score

67
5d
70
1 mentions
—
30d
66
5 mentions
—
60d
65
8 mentions
—
90d
66
13 mentions
—
news: 13

Analyst Ratings

6 analysts
Buyconsensus
Strong Buy 0Buy 6Hold 0Sell 0Strong Sell 0
Avg price target$18.5+540.1%
Low $10Median $19.5High $25
Current Consensus

Revenue

$0.00-100.00%
$0.00$177.0K$354.0K$531.0K
Mar 2022Sep 2026

Analyst Estimates

FY2025
$-1.95
$-2.07–$-1.73
8 analysts
FY2026
$-1.31
$-1.40–$-1.26
6 analysts
FY2027
$-1.45
$-1.75–$-1.15
7 analysts

Consensus estimates, not results. Via Financial Modeling Prep.

Company Profile

CEO
R. Nolan Townsend
Sector
Healthcare
Industry
Biotechnology
Employees
63
Beta
1.65
Country
US
Piotroski score
3 / 9 (Weak)
Altman Z-score
2.16
www.lexeotx.com